United StatesHealthcare and life sciences2026 – ongoingBioMarin Pharmaceutical
AI drafting for a hypochondroplasia regulatory submission
BioMarin said AI produced regulatory document drafts in hours rather than weeks
Problem
Preparing regulatory documents required substantial drafting time from BioMarin's experts. The company wanted to shorten filing cycles while retaining expert review.
Approach
BioMarin used AI to generate first drafts of key documents for its FDA submission in hypochondroplasia. Experts reviewed and refined the drafts before use. The company did not identify the model or supplier.
Results
No published figures
Takeaway
The reported time saving applied to first drafts. BioMarin did not quantify the reduction in the complete filing cycle.
Categories
- Industry
- Healthcare and life sciences
- Business function
- Finance, risk and legalIT and R&D
- Innovation type
- Process innovation
- AI technology
- Generative AI
- Adoption
- Built in-house
- Evidence
- Company's own claim
Sources
Source summaries
BioMarin's digital and information chief described AI drafting used in a recent hypochondroplasia FDA submission. He said first drafts took hours rather than weeks, with experts responsible for review and refinement.
Full details are in the original sources.
